ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that it has received approval to enrol its first adult patient at the Joondalup Health Campus (JHC) in Perth, Western Australia. The Emergency Department (ED) at JHC provides emergency services to nearly 100,000 patients per year (80,000 adults and 20,000 children), making it one of Australia’s busiest EDs. The study will gather data from adults presenting to the ED with respiratory conditions such as upper respiratory tract infections, bronchitis, pneumonia, asthma and chronic obstructive pulmonary disease. The aim of the study is to demonstrate that ResApp’s technology, shown to be highly accurate for diagnosis of childhood respiratory conditions, can be extended to adults.
JHC Director of Medical Services, Dr Simon Wood said, “We are pleased to again work with The University of Queensland and ResApp to extend the very successful childhood study into adult patients. We look forward to seeing how digital health technologies can be integrated into the practice of medicine and improve patient care.”
“We are excited to extend our clinical study to adults as an important next step for the company,” said Dr Tony Keating, CEO and Managing Director of ResApp. “With over 450 children enrolled in our paediatric study in just eight months, we have demonstrated the robustness of our machine learning algorithms to accurately diagnose the majority of childhood respiratory diseases. Including adults in the JHC study not only provides access to one of Australia’s busiest EDs, it utilises much of the same clinical team and logistics allowing us to achieve fast adult patient enrolment.”
ResApp will again work with The University of Queensland to analyse the clinical data and is targeting enrolment of 400 patients with preliminary results expected in the first half of calendar 2016.
ResApp plans to extend the adult study to a second site, one of the largest private emergency departments on the east coast of Australia. In-principle support has been given and the company plans to submit an application to that hospital’s Human Research Ethics Committee this month.
– ENDS –
About ResApp Health Limited
ResApp Health Limited, founded in 2014, is developing smartphone medical applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has a multi-site clinical study underway and preliminary results demonstrated accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children. Approval has been recently received to extend the study to adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.